Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Idelalisib activates AKT via increased recruitment of PI3Kδ/PI3Kβ to BCR signalosome while reducing PDK1 in post-therapy CLL cells

Leukemia(2022)10.1038/s41375-022-01595-0Source: DataRank Database

Idelalisib activates AKT via increased recruitment of PI3Kδ/PI3Kβ to BCR signalosome while reducing PDK1 in post-therapy CLL cells is a research paper published in Leukemia (2022). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.55)OA: greenTopics (45)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Hasan Mahmud ORCID,Guru Prasad Maiti ORCID,Mariana T. Mendez,Stacey M. Fernandes ORCID,Sara K. Vesely ORCID

Live enrichment

PubMed:35568768 PMC:PMC10874218 OpenAlex:https://openalex.org/W4280527022

NCI NIH HHS

Grant: R01 CA213442

NCI NIH HHS

Grant: P30 CA225520

NCI NIH HHS

Grant: R01 CA170006

National Institutes of Health

Grant: 5R01CA170006-06

Microvesicle Dynamics in B-Cell Chronic Lymphocytic Leukemia Tumor Microenvironme

National Institutes of Health

Grant: 3P30CA225520-06S4

Stephenson Cancer Center - Cancer Center Support Grant

National Institutes of Health

Grant: 5R01CA213442-05

Unlocking the Potential of PI3K Inhibition in CLL

FWCI

0.55

Citation Percentile

0.6%

Citation Trend

2023

2024

2026

greenLicense: Springer TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10874218/pdf/nihms-1873569.pdf

GREENhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874218

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10874218/pdf/nihms-1873569.pdf

publisherhttps://www.nature.com/articles/s41375-022-01595-0.pdf

publisherhttps://www.nature.com/articles/s41375-022-01595-0

Fields of Study

Chronic Lymphocytic Leukemia ResearchPI3K/AKT/mTOR signaling in cancerRenal Diseases and GlomerulopathiesMedicine0301 basic medicine0303 health sciences03 medical and health sciencesClass I Phosphatidylinositol 3-KinasesHumansLeukemia, Lymphocytic, Chronic, B-CellProto-Oncogene Proteins c-aktPurinesPyruvate Dehydrogenase Acetyl-Transferring KinaseQuinazolinones

MeSH Terms

Pyruvate Dehydrogenase Acetyl-Transferring KinaseHumansPurinesLeukemia, Lymphocytic, Chronic, B-CellProto-Oncogene Proteins c-aktQuinazolinonesClass I Phosphatidylinositol 3-Kinases

Keywords

IdelalisibPI3K/AKT/mTOR pathwayProtein kinase Bbreakpoint cluster regionCancer researchCD19Cell biologyChemistrySignal transductionBiologyChronic lymphocytic leukemiaReceptorCellImmunologyBiochemistryLeukemiaIbrutinibClass I Phosphatidylinositol 3-KinasesPurinesHumansPyruvate Dehydrogenase Acetyl-Transferring KinaseLeukemia, Lymphocytic, Chronic, B-CellProto-Oncogene Proteins c-aktQuinazolinones

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Idelalisib activates AKT via increased recruitment of PI3Kδ/PI3Kβ to BCR signalosome while reducing PDK1 in post-therapy CLL cells

FAIR Checklist

Authors (9)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)